Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Ji G. Wang"'
Autor:
De-Wei An, Yuehua Li, Qi-Fang Huang, Chang-Sheng Sheng, Dong-Yan Zhang, Qian-Hui Guo, Yi-Bang Cheng, Ji G. Wang
Publikováno v:
Journal of Hypertension. 36:e103
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9969f3c96dafd68c9b8c3314c9170f6
https://doi.org/10.1097/01.hjh.0000539266.80583.8c
https://doi.org/10.1097/01.hjh.0000539266.80583.8c
Autor:
Dong-Yan Zhang, Yi-Bang Cheng, Qi-Fang Huang, Yuehua Li, Ji G. Wang, Chang-Sheng Sheng, Qian-Hui Guo
Publikováno v:
Journal of Hypertension. 35:e243
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e8effd45ef93ac2b394d3c49876c064
https://doi.org/10.1097/01.hjh.0000523703.87838.03
https://doi.org/10.1097/01.hjh.0000523703.87838.03
Autor:
A Ryabikov, Tatiana Kuznetsova, Jerzy Gasowski, Ji G. Wang, Jan A. Staessen, Yuri Nikitin, Robert Fagard
Publikováno v:
Scopus-Elsevier
This meta-analysis attempted to derive pooled estimates for the putative association between echocardiographic or electrocardiographic left ventricular hypertrophy and the deletion/insertion (D/I) polymorphism of the angiotensin-I converting enzyme.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10106a5c200b62537e44e20ee94a1769
https://doi.org/10.1038/sj.jhh.1001055
https://doi.org/10.1038/sj.jhh.1001055
Autor:
Jerzy Gasowski, François Gueyffier, Robert Fagard, Lutgarde Thijs, Elly Den Hond, John Coope, Lisheng Liu, Tork Ekbom, Jean-Pierre Boissel, Ji G. Wang, Jan A. Staessen, Stuart J. Pocock, Karla Kerlikowske
Publikováno v:
The Lancet. 355:865-872
Summary Background Previous meta-analysis of outcome trials in hypertension have not specifically focused on isolated systolic hypertension or they have explained treatment benefit mainly in function of the achieved diastolic blood pressure reduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92e37b2ecac37470ab67cdba3ca63162
https://doi.org/10.1016/s0140-6736(99)07330-4
https://doi.org/10.1016/s0140-6736(99)07330-4
Publikováno v:
Journal of Human Hypertension. 13:859-863
Aims: Isolated systolic hypertension affects over 8 to 15% of all subjects older than 60 years. In the elderly, systolic hypertension is the major modifiable cardiovascular risk factor. Three placebo-controlled outcome trials on antihypertensive drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f58ad2b191a201751b01ce8ab107c8
https://doi.org/10.1038/sj.jhh.1000899
https://doi.org/10.1038/sj.jhh.1000899
Publikováno v:
Current Hypertension Reports. 1:387-393
Isolated systolic hypertension affects 8% to 15% of all people older than 60 years of age. In the elderly, systolic hypertension is the major modifiable cardiovascular risk factor. Three placebo-controlled outcome trials on antihypertensive drug trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d621f1268fafe7b10be0668079979c75
https://doi.org/10.1007/s11906-999-0053-2
https://doi.org/10.1007/s11906-999-0053-2
Publikováno v:
European Journal of Internal Medicine. 10:82-87
Isolated systolic hypertension affects over 15% of all subjects older than 60 years. In the elderly, systolic hypertension is the major modifiable cardiovascular risk factor. Three placebo-controlled outcome trials on antihypertensive drug treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08d0ef403fc52cfeedf8b50550875334
https://doi.org/10.1016/s0953-6205(99)00027-8
https://doi.org/10.1016/s0953-6205(99)00027-8
Publikováno v:
European Heart Journal. 20:11-30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8deb5e442cf7a7491151c38336bd25e
https://doi.org/10.1053/euhj.1998.1121
https://doi.org/10.1053/euhj.1998.1121
Autor:
Yawei Xu, Athanase D. Protogerou, Chen Chi, Yan Zhang, Ji G. Wang, Michel E. Safar, Jacques Blacher, C. Tai
Publikováno v:
Journal of Hypertension. 33:e19-e20
Objective:Current clinical evidence and latest guidelines recommended the combination antihypertensive therapy with angiotensin-converting enzyme (ACE) inhibitor / angiotensin receptor blocker (ARB) and calcium channel blocker (CCB) in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e027b53e0778d746c18e5e2fd86d68aa
https://doi.org/10.1097/01.hjh.0000467402.25796.00
https://doi.org/10.1097/01.hjh.0000467402.25796.00
Autor:
Yuan-Yuan Kang, Fang-Fei Wei, J.A. Staessen, L. Thijs, Ting-Yan Xu, Yan Li, S. Wang, L. Zhang, Ji G. Wang
Publikováno v:
Journal of Hypertension. 33:e39
Objective:Hypertension guidelines propose home (HBP) or ambulatory (ABP) blood pressure monitoring as indispensable after office measurement (OBP). However, whether preference should be given to HBP or ABP remains undetermined.Design and method:We re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5097ee50e664f922790b9c87c32c38ca
https://doi.org/10.1097/01.hjh.0000467453.47773.9e
https://doi.org/10.1097/01.hjh.0000467453.47773.9e